{{Rsnum
|rsid=1799978
|Gene=DRD2
|Chromosome=11
|position=113475629
|Orientation=minus
|GMAF=0.1051
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=DRD2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 90.3 | 9.7 | 0.0
| HCB | 69.9 | 25.0 | 5.1
| JPT | 79.6 | 20.4 | 0.0
| YRI | 72.1 | 25.9 | 2.0
| ASW | 77.2 | 21.1 | 1.8
| CHB | 69.9 | 25.0 | 5.1
| CHD | 56.9 | 35.8 | 7.3
| GIH | 89.1 | 10.9 | 0.0
| LWK | 66.4 | 25.5 | 8.2
| MEX | 79.3 | 20.7 | 0.0
| MKK | 71.8 | 27.6 | 0.6
| TSI | 92.2 | 7.8 | 0.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=19373123
|Title=Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution
}}

{{PharmGKB
|RSID=rs1799978
|Name_s=DRD2:A-241G
|Gene_s=DRD2
|Feature=
|Evidence=PubMed ID:19339912
|Annotation=Risk or phenotype-associated allele: A. Phenotype: Having the AA genotype of this variant was associated with a protective effect from increased prolactin concentration. Study size: 90. Study population/ethnicity: 7-17-year-old patients chronically treated with risperidone; non-Hispanic Caucasians. Significance metric(s): p = 0.002. Type of association: CO.
|Drugs=risperidone
|Drug Classes=
|Diseases=Hyperprolactinemia
|Curation Level=Curated
|PharmGKB Accession ID=PA165108051
}}

{{PMID Auto
|PMID=19512960
|Title=Genetic diagnostics of functional variants of the human dopamine D2 receptor gene
}}

{{PharmGKB
|RSID=rs1799978
|Name_s=DRD2: -241A>G
|Gene_s=DRD2
|Feature=
|Evidence=PubMed ID:18855532
|Annotation=This SNP is significant predictor of treatment response to risperidone in first-episode schizophrenia.
|Drugs=risperidone
|Drug Classes=
|Diseases=Schizophrenia
|Curation Level=Curated
|PharmGKB Accession ID=PA162356251
}}

{{PMID|18305461|OA=1
}} Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety.

{{PMID|18330705|OA=1
}} Physiogenomic analysis of localized FMRI brain activity in schizophrenia.

{{PMID|19968402|OA=1
}} Evaluation of genetic variability in the dopamine receptor D2 in relation to behavioral inhibition and impulsivity/sensation seeking: an exploratory study with d-amphetamine in healthy participants.

{{PMID|21162693|OA=1
}} Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1799978
|overall_frequency_n=21
|overall_frequency_d=128
|overall_frequency=0.164062
|n_genomes=17
|n_genomes_annotated=0
|n_haplomes=19
|n_articles=2
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23828101
|Title=Impulsivity and genetic variants in DRD2 and ANKK1 moderate longitudinal associations between sleep problems and overweight from ages 5 to 11.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}